SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc

Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytok...

Descripción completa

Detalles Bibliográficos
Autor principal: Magro, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224649/
https://www.ncbi.nlm.nih.gov/pubmed/32421092
http://dx.doi.org/10.1016/j.cytox.2020.100029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224649/
https://www.ncbi.nlm.nih.gov/pubmed/32421092
http://dx.doi.org/10.1016/j.cytox.2020.100029

Ejemplares similares